Glabridin Market Size, Share, Growth, and Global Industry Analysis by Type (20% [HPLC], 40%, 60% [HPLC], 90% [HPLC], 98% [HPLC], and Others), By Application (Cosmetic and Pharmaceuticals), Regional Insights, and Forecast To 2031

GLABRIDIN MARKET REPORT OVERVIEW

• 

•  Request a Free Sample to learn more about this report

The global glabridin market size was USD 20 million in 2022 and is projected to touch USD 29.93 million by 2031, exhibiting a CAGR of 4.8% during the forecast period.

Glabridin is a chemical substance that is present in the root extract of licorice or glycyrrhiza glabra. It is a type of isoflavonoid called isoflavane. Glabridin belongs to a family of plant-derived molecules, the natural phenols. It is present in a yellowish-brown powder form. Glabridin is soluble in organic solvents such as propylene glycol. But it is not soluble in water. It has proved efficient as a skin lightening agent. Glabridin spontaneously acts to block tyrosinase; which is an enzyme responsible for skin darkening. It also has properties to moisturize dry skin.

The global glabridin market is predicted to grow rapidly over the years. The glabridin market has seen several developments in its applications which is assisting the global glabridin market growth. It has a range of pharmacological properties such as anti-inflammatory, anti-cancer, anti-bacterial, regulating blood lipids and glucose level. The versatility of this compound has led to its increasing usage. Hence the global glabridin market share is predicted to increase.

COVID-19 Impact: Versatility of the Product Boosted Application in Clinical Trials

The global COVID-19 pandemic has been unprecedented and staggering, with photochromic materials experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The spike in CAGR is attributable to the glabridin market growth and demand returning to pre-pandemic levels once the pandemic is over.

COVID-19 had a life changing impact globally. The global glabridin market was significantly affected. The virus had various impacts on different markets. Lockdowns were imposed in several nations. This erratic pandemic caused disruptions on all sorts of businesses. Restrictions tightened during the pandemic due to increasing number of cases. Numerous Industries were affected. However, the market for glabridin experienced a major boost.

Glabridin was widely studied since the outbreak of COVID-19. It was used majorly used in the clinical trials of COVID-19. Glabridin synthesized the inflammatory points and mediators by blocking the binding of ACE 2 to virus spike protein and exert antiviral and antibacterial effects. It proved vital in improving the symptoms of fever, dry cough and breathlessness. Research established by Qian-hui Zhang stated that it has the potential to adjuvant prevent and treat early/mild COVID-19. It was also established that glabridin was easily absorbed by the human blood without any side effects.

As people were getting used to the stay-at-home norms, people indulged into social activities via digital media. This resulted in an increased usage of glabridin as a cosmetic element. Cosmetics applications held a major share of the market during 2020. This discovery of glabridin is anticipated to increase the global glabridin market size.

LATEST TRENDS

"Continuous R&D and New Discoveries to Benefit Market Prospects"

The global photochromic market growth is anticipated to increase owing to recent discoveries led by experimentation. A recent research paper published on PubMed Central experimenting on isoflavonids against phytopathogenic fungi concluded that glabridin could induce reactive oxygen species accumulation and the loss of mitochondrial membrane potential. This result indicated that glabridin has the potential to serve as a fungicidal candidate.

An article published on the International Society of Oncology and BioMarkers states that it conducted an experiment testing glabridin against Braf and MEK1/2 molecules. The data from the experiment indicated that glabridin could inhibit the phosphorylation of MEK1/2. This concluded with the result that glabridin is a potential multi-molecule targeting inhibitor in the field of clinical prevention or treatment of cancer.

GLABRIDIN MARKET SEGMENTATION

• 
•  Request a Free Sample to learn more about this report

• By Type

Based on type, the market is divided into 20% [HPLC], 40% [HPLC], 60% [HPLC], 90% [HPLC], 98% [HPLC], and others. Among these, 40% [HPLC] segment is expected to capture the leading share in the market through 2028.

• By Application

Based on application, the market is bifurcated into cosmetic and pharmaceutical. The cosmetic segment is anticipated to account for the major share of the market in the coming years.

DRIVING FACTORS

"Metabolic Effects to Expand Application Potential in Diabetes Drugs"

A research article on cogent food and agriculture published on Taylor & Francis Online investigated the metabolic effects of glabridin. The investigation concluded that patients with type 2 diabetes who consume glabridin daily indicated an improved flow-mediated vasodilation. A survey established by WHO indicates that 422 million people in the world have diabetes. Out of which 95% of the people have type 2 diabetes. According to International Diabetes Federation, the number is expected to reach to 643 million by 2030. This increase in diabetic patients would directly influence the use the glabridin, which holds immense potential as an effective ingredient in diabetes care products and drugs.

"Increased Cancer Patients to Increase the Use of Glabridin in Pharmaceutical Research"

The global glabridin market growth is anticipated to spike owing to the increase in the number of aged people across the globe. An article published on NCBI has stated that glabridin inhibits the malignant proliferation of human gastric cancer cell line. With the increasing number of old aged people, there will be a rise in several types of cancers as elderly individuals are more vulnerable. There has also been a drastic rise in the number of cancer patients. The data published by NCBI indicated that the p16 is a novel target for gastric cancer therapy. The International Agency for Research on Cancer [IRAC] updated the Globocon data of 2020 with an estimated 19.3 million cancer cases. Therefore, the rising stress of cancer cases would boost the growth of the global glabridin market.

RESTRAINING FACTORS

"Hypoglycemic Effects to Hinder Appeal of the Product in Certain Applications"

There are several factors that could affect the global glabridin market growth. The growth of the market is mainly due to side effects of increased body weight. A study on hypoglycemic effects of glabridin published on Research Gate concluded that the glabridin significantly increased the body weight. This could cause a negative appeal to the obese community that is diagnosed with cancer or diabetes. A paradigm such as this has the tendency to restrict and limit the market growth.

GLABRIDIN MARKET REGIONAL INSIGHTS

• 
•  Request a Free Sample to learn more about this report

"Asia Pacific Dominates the Market as Root of Development "

Asia Pacific countries are a major producer for glabridin market. Asia Pacific was among the first regions where the properties of glabridin were discovered and used. The countries developed the pharmaceuticals based in and around glabridin as it proved to be a useful cure for various ailments. The growing burden of various health problems in this region along with a booming elderly population base creates a favorable growth outlook for the market in this region. North America, led by the U.S., is among the major consumers in the global glabridin market and will create substantial demand in the future.

KEY INDUSTRY PLAYERS

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

LIST OF TOP GLABRIDIN COMPANIES

·       Sabinsa [U.S.]

·       Alchem International [India]

·       MAFCO Worldwide [U.S.]

·       Plamed Green Science Group [China]

·       Xi'an Zhongyang Electric Co Ltd [China]

·       Nanjing Spring & Autumn Biological [China]

·       Huaian Brothers Biotechnology [China]

·       Xi’an Tianye Biotech [China]

·       Maruzen Pharmaceuticals [Japan]

·       SK Bioland [South Korea]

·       Sunpure Extracts [India]

REPORT COVERAGE

This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. The studies also offer a detailed analysis by identifying factors such as segmentation, advancements in the industry, growth, size, share and constraints. These analytics are subject to change if the key players and probable analysis of market dynamics changes.